Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Pharmacol., 20 January 2026

Sec. Ethnopharmacology

Volume 16 - 2025 | https://doi.org/10.3389/fphar.2025.1758996

Correction: Cannabis-based extract for managing pain in dogs with osteoarthritis: efficacy and safety assessment

This article is a correction to:

  1. Cannabis-based extract for managing pain in dogs with osteoarthritis: efficacy and safety assessment

    1. Read original article
Neide Maria Griebeler&#x;Neide Maria Griebeler1†Ricardo Penayo Cremonese&#x;Ricardo Penayo Cremonese1†Yasmin Rafaela Fakih CorreaYasmin Rafaela Fakih Correa1Priscila Romero Mazzini PereiraPriscila Romero Mazzini Pereira1Amanda Furjan RialAmanda Furjan Rial2Emanuela LeiteEmanuela Leite1Maria Victoria Luz GonalvesMaria Victoria Luz Gonçalves1Luiz Renato Marques das AlmasLuiz Renato Marques das Almas3Nedice Borges CardosoNedice Borges Cardoso4Fernando Cezar-dos-SantosFernando Cezar-dos-Santos1Aline Theodoro TociAline Theodoro Toci4Andrs Mojoli Le-QuesneAndrés Mojoli Le-Quesne1Francisney Pinto Nascimento Francisney Pinto Nascimento1*
  • 1Laboratory of Cannabis and Psychedelics - LCP, Universidade Federal da Integração Latino Americana (UNILA), Foz do Iguaçu, Brazil
  • 2POP-VET Veterinary Hospital, Foz do Iguaçu, Brazil
  • 3Associação Santa Cannabis, Florianópolis, Brazil
  • 4Environmental and Food Interdisciplinary Studies Laboratory - LEIMAA, Universidade Federal da Integração Latino Americana (UNILA), Foz do Iguaçu, Brazil

A Correction on
Cannabis-based extract for managing pain in dogs with osteoarthritis: efficacy and safety assessment

by Griebeler NM, Cremonese RP, Fakih Correa YR, Pereira PRM, Rial AF, Leite E, Gonçalves MVL, Marques das Almas LR, Cardoso NB, Cezar-dos-Santos F, Toci AT, Mojoli Le-Quesne A and Nascimento FP (2025). Front. Pharmacol. 16:1539704. doi: 10.3389/fphar.2025.1539704

The figure captions were in the wrong order in the PDF/HTML version of this paper. Figure 1 had the caption of Figure 2; Figure 2 had the caption of Figure 1; Figure 3 had the caption of Figure 6; Figure 4 had the caption of Figure 3. The order has now been corrected.

Figure 1
Pie chart showing cannabinoid composition of an extract with corresponding daily doses in milligrams per kilogram. Cannabidiol is 64.32% (7.80 mg/kg), Cannabichromene 2.99% (0.36 mg/kg), Delta-9-tetrahydrocannabinol 2.45% (0.30 mg/kg), Cannabigerolic Acid 2.37% (0.28 mg/kg), Cannabigerol 1.49% (0.18 mg/kg), Cannabidivarin 1.26% (0.16 mg/kg), Cannabidiolic Acid 0.64% (0.076 mg/kg), and Others 24.50% (3.00 mg/kg).

Figure 1. Cannabinoids present in the extract provided by the Santa Cannabis Association.

Figure 2
Flowchart showing a randomized controlled trial. Thirty-three assessed for eligibility, seventeen randomized: eight to placebo (MCT), nine to cannabis oil. Sixteen excluded: nine for criteria, four deaths, three others. Follow-up and analysis conducted, with reasons for withdrawal noted: one withdrew from each group, and the cannabis group had one missed appointment. Final analysis included seven participants from each group.

Figure 2. Flowchart of patient triage. This image summarizes the animal selection and study methodology over 90 days, representing the excluded animals and treatment groups.

Figure 3
Four line graphs compare the effects of cannabis oil and placebo over time. Graph A shows Helsinki Chronic Pain Index (HCPI) scores decreasing for both groups. Graph B indicates a decrease in CBPI Severity; cannabis oil shows variation at T90. Graph C shows CBPI Interference scores slightly decreasing for both groups. Graph D depicts CBPI Quality of Life with an initial increase, then a decrease; cannabis oil shows fluctuations. Cannabis oil is represented in green, placebo in black.

Figure 3. Graphical representation of HCPI and CBPI outcomes.

Figure 4
Five line graphs show the effects of cannabis oil versus placebo on joint mobility, lameness, pain on palpation, weight-bearing, and overall clinical condition over time. Graph A depicts joint mobility scores; cannabis oil shows slight improvement over 90 days. Graph B shows lameness scores, with cannabis oil reducing lameness. Graph C illustrates pain on palpation scores, showing decrease with cannabis oil. Graph D displays weight-bearing scores, with cannabis oil improving outcomes. Graph E indicates overall clinical condition scores, where cannabis oil shows notable improvement. Each graph includes a legend for cannabis oil and placebo.

Figure 4. Graphical summary of veterinary clinical assessment outcomes.

Furthermore, there was a mistake in the caption of Figure 5 as published. Figure 5 had the caption of Figure 6. The corrected caption of Figure 5 appears below.

Figure 5
Graphs illustrate effects of cannabis oil versus placebo on various liver and blood parameters over time. Each chart shows data at T0, T30, and T90 days post-treatment. A: Alkaline phosphatase increases significantly with cannabis oil. B: Alanine aminotransferase remains stable. C: Aspartate aminotransferase shows minor fluctuations. D: Gamma-glutamyl transferase increases with cannabis oil. E: Total protein is unchanged. F: Albumin slightly decreases with cannabis oil. G: Globulin shows a minor increase. H: Ratio A/G decreases slightly with cannabis oil. Error bars indicate variability.

Figure 5. Biochemical marker levels during the 90-day treatment period. Part I. *p < 0.05 for significant differences between cannabis oil and placebo groups. (A) p < 0.05 for significant differences between time points 0 and 30 within the placebo group. (B) P < 0.05 for significant differences between time points 0 and 30 within the cannabis oil group. (C) p < 0.05 for significant differences between time points 0 and 90 within the cannabis oil group. (D) p < 0.05 for significant differences between time points 30 and 90 within the cannabis oil group. (E) p < 0.05 for significant differences between time points 30 and 90 within the placebo group.

Figure 6
Eight line graphs labeled A to H compare the effects of cannabis oil and placebo over time on various measures: bilirubin, direct bilirubin, indirect bilirubin, creatinine, cholesterol, triglycerides, urea, and glucose. Each graph shows values at days zero, thirty, and ninety post-treatment. Cannabis oil data is in green, placebo in black. Error bars indicate variability.

Figure 6. Biochemical marker levels during the 90-day treatment period. Part II.*p < 0.05 for significant differences between cannabis oil and placebo groups. (A) P < 0.05 for significant differences between time points 0 and 30 with in the placebo group. (B) P < 0.05 for significant differences between time points 0 and 30 with in the cannabis oil group. (C) P < 0.05 for significant differences between time points 0 and 90 with in the cannabis oil group. (D) P < 0.05 for Q27 significant differences between time points 30 and 90 with in the cannabis oilgroup. (E) P < 0.05 for significant differences between time points 30 and 90 with in the placebo group.

There was also a mistake in the caption of Figure 6 as published. Figure 6 had the caption of Figure 3. The corrected caption of Figure 6 appears below.

The original article has been updated.

Generative AI statement

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: adverse events, cannabinoids, canine, efficacy, osteoarthritis, quality of life, safety

Citation: Griebeler NM, Penayo Cremonese R, Correa YRF, Pereira PRM, Rial AF, Leite E, Gonçalves MVL, das Almas LRM, Cardoso NB, Cezar-dos-Santos F, Toci AT, Le-Quesne AM and Nascimento FP (2026) Correction: Cannabis-based extract for managing pain in dogs with osteoarthritis: efficacy and safety assessment. Front. Pharmacol. 16:1758996. doi: 10.3389/fphar.2025.1758996

Received: 02 December 2025; Accepted: 22 December 2025;
Published: 20 January 2026.

Edited and reviewed by:

Javier Echeverria, University of Santiago, Chile

Copyright © 2026 Griebeler, Penayo Cremonese, Correa, Pereira, Rial, Leite, Gonçalves, das Almas, Cardoso, Cezar-dos-Santos, Toci, Le-Quesne and Nascimento. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Francisney Pinto Nascimento, ZnJhbmNpc25leS5uYXNjaW1lbnRvQHVuaWxhLmVkdS5icg==

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.